行业分析 |
|
|
|
|
靶向蛋白降解药物市场分析及建议* |
刘少金1,**(),窦树珍1,王俊姝1,吴海明2,邹慧1 |
1 江西省科学院科技战略研究所 南昌 330096 2 瀚芯医疗科技(深圳)有限公司 深圳 518109 |
|
Market Analysis and Countermeasures for Targeted Protein Degradation Drugs |
LIU Shao-jin1,**(),DOU Shu-zhen1,WANG Jun-shu1,WU Hai-ming2,ZOU Hui1 |
1 Institute of Science and Technology Strategy, Jiangxi Academy of Sciences, Nanchang 330096, China 2 Halocinch Medical Technology (Shenzhen) Co., Ltd, Shenzhen 518109, China |
引用本文:
刘少金, 窦树珍, 王俊姝, 吴海明, 邹慧. 靶向蛋白降解药物市场分析及建议*[J]. 中国生物工程杂志, 2023, 43(2/3): 190-200.
LIU Shao-jin, DOU Shu-zhen, WANG Jun-shu, WU Hai-ming, ZOU Hui. Market Analysis and Countermeasures for Targeted Protein Degradation Drugs. China Biotechnology, 2023, 43(2/3): 190-200.
链接本文:
https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.2210018
或
https://manu60.magtech.com.cn/biotech/CN/Y2023/V43/I2/3/190
|
[1] |
Burslem G M, Crews C M. Small-molecule modulation of protein homeostasis. Chemical Reviews, 2017, 117(17): 11269-11301.
doi: 10.1021/acs.chemrev.7b00077
pmid: 28777566
|
[2] |
Verdine G L, Walensky L D. The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 2007, 13(24): 7264-7270.
doi: 10.1158/1078-0432.CCR-07-2184
|
[3] |
Samarasinghe K T G, Crews C M. Targeted protein degradation: a promise for undruggable proteins. Cell Chemical Biology, 2021, 28(7): 934-951.
doi: 10.1016/j.chembiol.2021.04.011
pmid: 34004187
|
[4] |
Cromm P M, Crews C M. Targeted protein degradation: from chemical biology to drug discovery. Cell Chemical Biology, 2017, 24(9): 1181-1190.
doi: S2451-9456(17)30187-3
pmid: 28648379
|
[5] |
Naito M. Targeted protein degradation and drug discovery. The Journal of Biochemistry, 2022, 172(2): 61-69.
doi: 10.1093/jb/mvac041
|
[6] |
张晓元, 张艳艳, 孙晓康, 等. 靶向蛋白质降解技术研究进展. 生物化学与生物物理进展, 2022, 49(1): 171-182.
|
|
Zhang X Y, Zhang Y Y, Sun X K, et al. Research progress of targeted protein degradation technology. Progress in Biochemistry and Biophysics, 2022, 49(1): 171-182.
|
[7] |
Wang C, Zhang Y J, Zhang T T, et al. Proteolysis-targeting chimaeras (PROTACs) as pharmacological tools and therapeutic agents: advances and future challenges. Journal of Enzyme Inhibition and Medicinal Chemistry, 2022, 37(1): 1667-1693.
doi: 10.1080/14756366.2022.2076675
pmid: 35702041
|
[8] |
Xi J Y, Zhang R Y, Chen K, et al. Advances and perspectives of proteolysis targeting chimeras (PROTACs) in drug discovery. Bioorganic Chemistry, 2022, 125: 105848.
doi: 10.1016/j.bioorg.2022.105848
|
[9] |
Zhao L, Zhao J, Zhong K H, et al. Targeted protein degradation: mechanisms, strategies and application. Signal Transduction and Targeted Therapy, 2022, 7: 113.
doi: 10.1038/s41392-022-00966-4
pmid: 35379777
|
[10] |
Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell, 1994, 79(1): 13-21.
doi: 10.1016/0092-8674(94)90396-4
pmid: 7923371
|
[11] |
Ballabio A, Bonifacino J S. Lysosomes as dynamic regulators of cell and organismal homeostasis. Nature Reviews Molecular Cell Biology, 2020, 21(2): 101-118.
doi: 10.1038/s41580-019-0185-4
pmid: 31768005
|
[12] |
Eldridge A G, O’Brien T. Therapeutic strategies within the ubiquitin proteasome system. Cell Death & Differentiation, 2010, 17(1): 4-13.
|
[13] |
Gustafson J L, Neklesa T K, Cox C S, et al. Small-molecule-mediated degradation of the androgen receptor through hydrophobic tagging. Angewandte Chemie (International Ed in English), 2015, 54(33): 9659-9662.
doi: 10.1002/anie.v54.33
|
[14] |
Weagel E G, Foulks J M, Siddiqui A, et al. Molecular glues: enhanced protein-protein interactions and cell proteome editing. Medicinal Chemistry Research, 2022, 31(7): 1068-1087.
doi: 10.1007/s00044-022-02882-2
|
[15] |
Sakamoto K M, Kim K B, Kumagai A, et al. Protacs:Chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98(15): 8554-8559.
|
[16] |
Metzger M B, Pruneda J N, Klevit R E, et al. RING-type E3 ligases: master manipulators of E 2 ubiquitin-conjugating enzymes and ubiquitination. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2014, 1843(1): 47-60.
doi: 10.1016/j.bbamcr.2013.05.026
|
[17] |
Luh L M, Scheib U, Juenemann K, et al. Prey for the proteasome: targeted protein degradation-a medicinal chemist’s perspective. Angewandte Chemie (International Ed in English), 2020, 59(36): 15448-15466.
|
[18] |
Banik S M, Pedram K, Wisnovsky S, et al. Lysosome-targeting chimaeras for degradation of extracellular proteins. Nature, 2020, 584(7820): 291-297.
doi: 10.1038/s41586-020-2545-9
|
[19] |
Cotton A D, Nguyen D P, Gramespacher J A, et al. Development of antibody-based PROTACs for the degradation of the cell-surface immune checkpoint protein PD-L1. Journal of the American Chemical Society, 2021, 143(2): 593-598.
doi: 10.1021/jacs.0c10008
pmid: 33395526
|
[20] |
Zhang H, Han Y, Yang Y F, et al. Covalently engineered nanobody chimeras for targeted membrane protein degradation. Journal of the American Chemical Society, 2021, 143(40): 16377-16382.
doi: 10.1021/jacs.1c08521
pmid: 34596400
|
[21] |
Takahashi D, Moriyama J, Nakamura T, et al. AUTACs: cargo-specific degraders using selective autophagy. Molecular Cell, 2019, 76(5): 797-810.e10.
doi: S1097-2765(19)30694-X
pmid: 31606272
|
[22] |
Fu Y H, Chen N X, Wang Z Y, et al. Degradation of lipid droplets by chimeric autophagy-tethering compounds. Cell Research, 2021, 31(9): 965-979.
doi: 10.1038/s41422-021-00532-7
pmid: 34239073
|
[23] |
Miao Y Y, Gao Q Q, Mao M H, et al. Bispecific aptamer chimeras enable targeted protein degradation on cell membranes. Angewandte Chemie (International Ed in English), 2021, 60(20): 11267-11271.
doi: 10.1002/anie.v60.20
|
[24] |
Ji C H, Kim H Y, Lee M J, et al. The AUTOTAC chemical biology platform for targeted protein degradation via the autophagy-lysosome system. Nature Communications, 2022, 13: 904.
doi: 10.1038/s41467-022-28520-4
pmid: 35173167
|
[25] |
Lin J Y, Jin J M, Shen Y W, et al. Emerging protein degradation strategies: expanding the scope to extracellular and membrane proteins. Theranostics, 2021, 11(17): 8337-8349.
doi: 10.7150/thno.62686
pmid: 34373745
|
[26] |
Ito T, Ando H, Suzuki T, et al. Identification of a primary target of thalidomide teratogenicity. Science, 2010, 327(5971): 1345-1350.
doi: 10.1126/science.1177319
pmid: 20223979
|
[27] |
Chanan-Khan A A, Swaika A, Paulus A, et al. Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. Blood Cancer Journal, 2013, 3(9): e143.
doi: 10.1038/bcj.2013.38
|
[28] |
Lopez-Girona A, Mendy D, Ito T, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia, 2012, 26(11): 2326-2335.
doi: 10.1038/leu.2012.119
pmid: 22552008
|
[29] |
Fischer E S, Böhm K, Lydeard J R, et al. Structure of the DDB1-CRBN E 3 ubiquitin ligase in complex with thalidomide. Nature, 2014, 512(7512): 49-53.
doi: 10.1038/nature13527
|
[30] |
Ozawa Y, Sugi N H, Nagasu T, et al. E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo. European Journal of Cancer, 2001, 37(17): 2275-2282.
pmid: 11677118
|
[31] |
Funahashi Y, Sugi N H, Semba T, et al. Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium. Cancer Research, 2002, 62(21): 6116-6123.
pmid: 12414636
|
[32] |
Abbate F, Casini A, Owa T, et al. Carbonic anhydrase inhibitors: E7070, a sulfonamide anticancer agent, potently inhibits cytosolic isozymes I and II, and transmembrane, tumor-associated isozyme IX. Bioorganic & Medicinal Chemistry Letters, 2004, 14(1): 217-223.
doi: 10.1016/j.bmcl.2003.09.062
|
[33] |
Mayor-Ruiz C, Bauer S, Brand M, et al. Rational discovery of molecular glue degraders via scalable chemical profiling. Nature Chemical Biology, 2020, 16(11): 1199-1207.
doi: 10.1038/s41589-020-0594-x
|
[34] |
Słabicki M, Kozicka Z, Petzold G, et al. The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K. Nature, 2020, 585(7824): 293-297.
doi: 10.1038/s41586-020-2374-x
|
[35] |
Winter G E, Buckley D L, Paulk J, et al. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science, 2015, 348(6241): 1376-1381.
doi: 10.1126/science.aab1433
pmid: 25999370
|
[36] |
Békés M, Langley D R, Crews C M. PROTAC targeted protein degraders: the past is prologue. Nature Reviews Drug Discovery, 2022, 21(3): 181-200.
doi: 10.1038/s41573-021-00371-6
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|